Related Experiment Video
Updated: Jun 6, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells
Quanri Jin1, Linda X Yuan, Delphine Boulbes
1Department of Breast Medical Oncology, The University of Texas M, D, Anderson Cancer Center, Houston, TX 77030, USA. qjin@mdanderson.org
Introduction:
The human epidermal growth factor receptor 2 (HER2) is a validated therapeutic target in breast cancer. Heterodimerization of HER2 with other HER family members results in enhanced tyrosine phosphorylation and activation of signal transduction pathways. HER2 overexpression increases the translation of fatty acid synthase (FASN), and FASN overexpression markedly increases HER2 signaling, which results in enhanced cell growth. However, the molecular mechanism and regulation of HER2 and FASN interaction are not well defined. Lapatinib is a small-molecule tyrosine kinase inhibitor that blocks phosphorylation of the epidermal growth factor receptor and HER2 in breast cancer cells, resulting in apoptosis. We hypothesized that FASN is directly phosphorylated by HER2, resulting in enhanced signaling and tumor progression in breast cancer cells.
Methods:
Using mass spectrometry, we identified FASN as one of the proteins that is dephosphorylated by lapatinib in SKBR3 breast cancer cells. Immunofluorescence, immunoprecipitation, Western blotting, a kinase assay, a FASN enzymatic activity assay, an invasion assay, a cell viability assay and zymography were used to determine the role of FASN phosphorylation in invasion of SKBR3 and BT474 cells. The FASN inhibitor C75 and small interfering RNA were used to downregulate FASN expression and/or activity.
Results:
Our data demonstrated that FASN is phosphorylated when it is in complex with HER2. FASN phosphorylation was induced by heregulin in HER2-overexpressing SKBR3 and BT474 breast cancer cells. Heregulin-induced FASN phosphorylation resulted in increased FASN enzymatic activity, which was inhibited by lapatinib. The FASN inhibitor C75 suppressed FASN activity by directly inhibiting HER2 and FASN phosphorylation. Blocking FASN phosphorylation and activity by lapatinib or C75 suppressed the activity of matrix metallopeptidase 9 and inhibited invasion of SKBR3 and BT474 cells.
Conclusions:
FASN phosphorylation by HER2 plays an important role in breast cancer progression and may be a novel therapeutic target in HER2-overexpressing breast cancer cells.
Insights
Fatty acid synthase (FASN) phosphorylation by human epidermal growth factor receptor 2 (HER2) drives breast cancer progression. Inhibiting this interaction with lapatinib or C75 may offer a novel therapeutic strategy for HER2-overexpressing breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Human epidermal growth factor receptor 2 (HER2) is a key target in breast cancer therapy.
- HER2 overexpression enhances fatty acid synthase (FASN) translation, promoting cell growth.
- The precise molecular mechanisms regulating HER2 and FASN interaction remain unclear.
Purpose of the Study:
- To investigate the hypothesis that HER2 directly phosphorylates FASN.
- To elucidate the role of FASN phosphorylation in breast cancer progression.
- To explore the therapeutic potential of targeting the HER2-FASN interaction.
Main Methods:
- Mass spectrometry identified FASN as a lapatinib-dephosphorylated protein in SKBR3 cells.
- Immunofluorescence, immunoprecipitation, Western blotting, and kinase assays were employed.
- FASN enzymatic activity, invasion, and cell viability assays were conducted using SKBR3 and BT474 cells.
Main Results:
- FASN was found to be phosphorylated when complexed with HER2.
- Heregulin induced FASN phosphorylation and increased its enzymatic activity in HER2-overexpressing cells.
- Lapatinib and the FASN inhibitor C75 blocked FASN phosphorylation and activity, inhibiting matrix metallopeptidase 9 and cell invasion.
Conclusions:
- FASN phosphorylation by HER2 is a critical factor in breast cancer progression.
- Targeting FASN phosphorylation by HER2 presents a potential novel therapeutic strategy.
- This interaction is particularly relevant in HER2-overexpressing breast cancers.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
11:13Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Phosphorylation
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...